ASX · IVX.AX
Invion Limited
A$0.04-A$0.00 (-5.41%)
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
Loading market information…
OTC · AQSZF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aequus Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aequus Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04-A$0.00 (-5.41%)
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
$0.00$0.00 (0.0%)
Rimrock Gold Corp.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$0.00$0.00 (0.0%)
Hemp Naturals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Golden Developing Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Todos Medical Ltd.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Bioasis Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Nexien BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.17% below the high.
$0.00$0.00 (0.0%)
Medicine Man Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.55% below the high.
